Earnings Scheduled For April 29, 2021 benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Quarterly Results
Earnings per share decreased 79.55% over the past year to $0.09, which beat the estimate of ($0.10).
Revenue of $486,030,000 decreased by 3.19% year over year, which beat the estimate of $446,450,000.
Looking Ahead
Earnings guidance hasn t been issued by the company for now.
The upcoming fiscal year s revenue expected to be between $1,750,000,000 and $1,850,000,000.
Details Of The Call
Time: 04:30 PM
ET Webcast URL: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=F1263B20-BE46-4ECA-876D-F6FFD8F51EF3&Referrer=https%3A%2F%2Finvestors.biomarin.com%2F
Recent Stock Performance
BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
- Full-year 2021 Financial Guidance Reaffirmed
- Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan
- Regulatory Actions in Europe for Vosoritide and Valoctocogene Roxaparvovec Tracking as Expected; BioMarin Anticipates CHMP Opinion in June for Vosoritide and June Re-submission of MAA for Valoctocogene Roxaparvovec
- FDA Review of Vosoritide Proceeding; PDUFA Target Action Date Extended to November 20, 2021 to Provide Time for Review of Recently Submitted 2-year Phase 3 Results
News provided by
Share this article
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
Allen Institute, BioMarin To Develop Gene Therapies For Rare Brain Diseases
WASHINGTON (dpa-AFX) - The Allen Institute and BioMarin Pharmaceutical Inc. (BMRN) announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system. They did not disclose financial terms.
BioMarin will receive an exclusive license to each program for research, development and commercialization.
The Allen Institute for Brain Science, a division of the Allen Institute, has developed modified adeno-associated viruses, or AAVs, that have been engineered to impact specific classes of cells in the brain.
Trillium Therapeutics (TRIL) Receives a Buy from Evercore ISI markets.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from markets.co Daily Mail and Mail on Sunday newspapers.